المؤلفون: Cortes JE; Georgia Cancer Center at Augusta University, Augusta, GA, USA. Jorge.Cortes@Augusta.edu., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kim DW; Uijeongbu Eulji Medical Center, Geumo-dong, Uijeongbu-si, South Korea., Hughes TP; South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, SA, Australia., Etienne G; Department of Hematology, Institut Bergonié, Bordeaux, France., Mauro MJ; Myeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Hochhaus A; Hematology/Oncology, Universitätsklinikum Jena, Jena, Germany., Lang F; Department of Medicine, Hematology and Oncology, Goethe University Hospital, Frankfurt, Germany., Heinrich MC; Portland VA Health Care System and OHSU Department of Medicine, Division of Hematology and Oncology, Knight Cancer Institute, Portland, OR, USA., Breccia M; Department of Translational and Precision Medicine-Az., Policlinico Umberto I-Sapienza University, Rome, Italy., Deininger M; Versiti Blood Research Institute, Milwaukee, WI, USA., Goh YT; Department of Haematology, Singapore General Hospital, Bukit Merah, Singapore., Janssen JJWM; Radboud University Medical Center, Nijmegen, The Netherlands., Talpaz M; Division of Hematology-Oncology, University of Michigan Rogel Cancer Center, Ann Arbor, MI, USA., de Soria VGG; Hospital Universitario La Princesa, Madrid, Spain., le Coutre P; Department of Oncology and Hematology, Charité - Universitätsmedizin Berlin, Berlin, Germany., DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA, USA., Damon A; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Cacciatore S; Novartis Pharma AG, Basel, Switzerland., Polydoros F; Novartis Pharma AG, Basel, Switzerland., Agrawal N; Novartis Pharma AG, Basel, Switzerland., Rea D; Department of Hématologie, Hôpital Saint-Louis, Paris, France.

المصدر: Leukemia [Leukemia] 2024 Jul; Vol. 38 (7), pp. 1522-1533. Date of Electronic Publication: 2024 May 16.

نوع المنشور: Journal Article; Clinical Trial, Phase I; Multicenter Study

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Protein Kinase Inhibitors*/therapeutic use , Protein Kinase Inhibitors*/adverse effects , Mutation* , Leukemia, Myeloid, Chronic-Phase*/drug therapy , Leukemia, Myeloid, Chronic-Phase*/genetics , Fusion Proteins, bcr-abl*/genetics , Fusion Proteins, bcr-abl*/antagonists & inhibitors, Humans ; Male ; Middle Aged ; Female ; Aged ; Adult ; Follow-Up Studies ; Aged, 80 and over ; Young Adult ; Drug Resistance, Neoplasm ; Antineoplastic Agents/therapeutic use ; Antineoplastic Agents/adverse effects ; Tyrosine Kinase Inhibitors ; Niacinamide/analogs & derivatives ; Pyrazoles

المؤلفون: Jabbour E; The University of Texas MD Anderson Cancer Center, Houston, TX, USA. ejabbour@mdanderson.org., Apperley J; Imperial College London, London, UK., Cortes J; Georgia Cancer Center, Augusta, GA, USA., Rea D; Hôpital Saint-Louis, Paris, France., Deininger M; Versiti Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI, USA., Abruzzese E; S. Eugenio Hospital, Tor Vergata University, Rome, Italy., Chuah C; Singapore General Hospital, National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, Singapore., DeAngelo DJ; Dana-Farber Cancer Institute, Boston, MA, USA., Hochhaus A; Universitätsklinikum Jena, Jena, Germany., Lipton JH; Princess Margaret Cancer Centre, Toronto, ON, Canada., Mauro M; Memorial Sloan Kettering, New York, NY, USA., Nicolini F; Centre Léon Bérard, Lyon, France., Pinilla-Ibarz J; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA., Rosti G; IRST/IRCCS 'Dino Amadori', Meldola (FC), Italy., Rousselot P; Hospital Mignot University de Versailles Saint-Quentin-en-Yvelines, Paris, France., Shah NP; University of California San Francisco, San Francisco, CA, USA., Talpaz M; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI, USA., Vorog A; Takeda Development Center Americas, Inc., Lexington, MA, USA., Ren X; Takeda Development Center Americas, Inc., Lexington, MA, USA., Kantarjian H; The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

المصدر: Leukemia [Leukemia] 2024 Mar; Vol. 38 (3), pp. 475-481. Date of Electronic Publication: 2024 Jan 29.

نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Chronic-Phase*/drug therapy , Leukemia, Myeloid, Chronic-Phase*/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Pyridazines*/therapeutic use , Pyridazines*/pharmacology , Antineoplastic Agents*/therapeutic use , Antineoplastic Agents*/pharmacology, Humans ; Drug Resistance, Neoplasm ; Imidazoles/therapeutic use ; Imidazoles/pharmacology ; Fusion Proteins, bcr-abl/genetics ; Protein Kinase Inhibitors/pharmacology

المؤلفون: Pepeler MS; Adult Hematology Deparment, Ankara Bilkent City Hospital, Ankara, Turkey. Electronic address: drsezgin44@gmail.com., Tıglıoglu M; Adult Hematology Deparment, Dıskapı Training and Research Hospital, Ankara, Turkey., Dagdas S; Adult Hematology Deparment, Ankara Bilkent City Hospital, Ankara, Turkey., Ozhamamcıoglu E; Pathology Department, Ankara Bilkent City Hospital, Ankara, Turkey., Han U; Pathology Department, Dıskapı Training and Research Hospital, Ankara, Turkey., Albayrak A; Pathology Department, Ankara Bilkent City Hospital, Ankara, Turkey., Aydın MS; Adult Hematology Deparment, Ankara Bilkent City Hospital, Ankara, Turkey., Korkmaz G; Adult Hematology Deparment, Ankara Bilkent City Hospital, Ankara, Turkey., Pamukcuoğlu M; Adult Hematology Deparment, Ankara Bilkent City Hospital, Ankara, Turkey., Ceran F; Adult Hematology Deparment, Ankara Bilkent City Hospital, Ankara, Turkey., Albayrak M; Adult Hematology Deparment, Dıskapı Training and Research Hospital, Ankara, Turkey., Ozet G; Adult Hematology Deparment, Ankara Bilkent City Hospital, Ankara, Turkey.

المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Apr; Vol. 24 (4), pp. e161-e167. Date of Electronic Publication: 2024 Jan 17.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

مواضيع طبية MeSH: Primary Myelofibrosis*/diagnosis , Primary Myelofibrosis*/drug therapy , Primary Myelofibrosis*/etiology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/pathology , Leukemia, Myeloid, Chronic-Phase*/drug therapy, Humans ; Female ; Middle Aged ; Male ; Prognosis ; Tyrosine Kinase Inhibitors ; Retrospective Studies ; Prospective Studies ; Fibrosis ; Protein Kinase Inhibitors/adverse effects

المؤلفون: Chelysheva E; National Medical Research Center for Hematology, Moscow, Russian Federation. denve@bk.ru., Apperley J; Centre for Haematology, Imperial College London, London, UK., Turkina A; National Medical Research Center for Hematology, Moscow, Russian Federation., Yassin MA; Department of Medical Oncology/ Hematology Section, National Centre For Cancer Care & Research, Doha, Qatar., Rea D; Service d'hématologie Adulte and FiLMC Hôpital Saint-Louis, Paris, France., Nicolini FE; Hematology department and INSERM 1052 CRCL, Centre Léon Bérard, Lyon, France., Barraco D; Division of Hematology, University Hospital 'Ospedale di Circolo e Fondazione Macchi - ASST Sette Laghi', Varese, Italy., Kazakbaeva K; Republician Specilized Scientific and Practical Medical Centre of Hematology, Tashkent, Uzbekistan., Saliev S; Republician Specilized Scientific and Practical Medical Centre of Hematology, Tashkent, Uzbekistan., Abulafia AS; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Campus, Petah-Tikva, Israel., Al-Kindi S; Department of Haematology, Sultan Qaboos University, Muscat, Oman., Byrne J; Centre for Clinical Haematology, Nottingham University Hospitals NHS Trust, Nottingham, England, UK., Robertson HF; Centre for Haematology, Imperial College London, London, UK., Cerrano M; Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Turin, Italy., Shmakov R; FSBI «National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov» Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation., Polushkina E; FSBI «National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I.Kulakov» Ministry of Healthcare of the Russian Federation, Moscow, Russian Federation., de Fabritiis P; Hematology, S. Eugenio Hospital, Tor Vergata University, ASL Roma2, Rome, Italy., Trawinska MM; Hematology, S. Eugenio Hospital, Tor Vergata University, ASL Roma2, Rome, Italy., Abruzzese E; Hematology, S. Eugenio Hospital, Tor Vergata University, ASL Roma2, Rome, Italy.

المصدر: Leukemia [Leukemia] 2024 Apr; Vol. 38 (4), pp. 788-795. Date of Electronic Publication: 2024 Feb 23.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myeloid, Chronic-Phase* , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy, Humans ; Female ; Pregnancy ; Imatinib Mesylate ; Protein Kinase Inhibitors/adverse effects ; Placenta ; Interferon-alpha/therapeutic use ; Treatment Outcome

المؤلفون: Smith BD; Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA. Electronic address: bdsmith@jhmi.edu., Brümmendorf TH; Department of Hematology, Oncology, Hemostaseology and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany; Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf (CIO ABCD), Aachen Bonn Cologne Düsseldorf, Germany., Roboz GJ; Weill Cornell Medicine, New York, NY, USA., Gambacorti-Passerini C; University of Milano-Bicocca, Monza, Italy., Charbonnier A; Institut Paoli Calmettes, Marseille, France., Viqueira A; Pfizer SLU, Madrid, Spain., Leip E; Pfizer Inc, Cambridge, MA, USA., Purcell S; Pfizer Ltd, London, UK., Goldman EH; Pfizer Inc, New York, NY, USA., Giles F; Developmental Therapeutics LLC, Chicago, IL, USA., Ernst T; Jena University Hospital, Jena, Germany., Hochhaus A; Jena University Hospital, Jena, Germany., Rosti G; IRCCS/IRST 'Dino Amadori', Meldola (FC), Italy.

المصدر: Leukemia research [Leuk Res] 2024 Apr; Vol. 139, pp. 107481. Date of Electronic Publication: 2024 Mar 11.

نوع المنشور: Clinical Trial, Phase IV; Journal Article; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Pergamon Press Country of Publication: England NLM ID: 7706787 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-5835 (Electronic) Linking ISSN: 01452126 NLM ISO Abbreviation: Leuk Res Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Leukemia, Myeloid, Chronic-Phase*/drug therapy , Aniline Compounds* , Nitriles* , Quinolines*, Humans ; Imatinib Mesylate/adverse effects ; Dasatinib/adverse effects ; Philadelphia Chromosome ; Protein Kinase Inhibitors/adverse effects ; Pyrimidines ; Pathologic Complete Response

المؤلفون: Klink AJ; Cardinal Health Specialty Solutions, Dublin, OH. Electronic address: andrew.klink@cardinalhealth.com., Keating SJ; Bristol Myers Squibb, Princeton, NJ., Brokars J; Bristol Myers Squibb, Princeton, NJ., Feinberg B; Cardinal Health Specialty Solutions, Dublin, OH., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX.

المصدر: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Mar; Vol. 24 (3), pp. 149-157. Date of Electronic Publication: 2023 Oct 20.

نوع المنشور: Observational Study; Journal Article

بيانات الدورية: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myeloid, Chronic-Phase*/drug therapy , Antineoplastic Agents*/therapeutic use, Adult ; Humans ; Dasatinib/therapeutic use ; Imatinib Mesylate/pharmacology ; Imatinib Mesylate/therapeutic use ; Retrospective Studies ; Cohort Studies ; Pyrimidines/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Treatment Outcome

المؤلفون: Brivio E; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Pennesi E; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Willemse ME; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Huitema ADR; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; The Netherlands Cancer Institute, Amsterdam, the Netherlands.; University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands., Jiang Y; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van Tinteren HDR; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van der Velden VHJ; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands., Beverloo BH; Department of Clinical Genetics, Erasmus MC, Rotterdam, the Netherlands., den Boer ML; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Rammeloo LAJ; Department of Pediatric Cardiology, Amsterdam UMC, Emma Children's Hospital, Amsterdam, the Netherlands., Hudson C; Hematologics Inc, Seattle, WA., Heerema N; Nationwide Children's Hospital, Columbus, OH., Kowalski K; Pfizer Inc, New York, NY., Zhao H; Pfizer Inc, New York, NY., Kuttschreuter L; Pfizer Inc, New York, NY., Bautista Sirvent FJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Pediatric Oncology and Hematology Department, Hospital Niño Jesús, Madrid, Spain., Bukowinski A; Pediatric Hematology and Oncology Alabama, University of Alabama at Birmingham, Birmingham, AL., Rizzari C; Department of Pediatrics, University of Milano-Bicocca, IRCCS San Gerardo dei Tintori, Monza, Italy., Pollard J; Dana-Farber/Harvard Cancer Center, Boston, MA., Murillo-Sanjuán L; Hospital Universitari Vall d'Hebron, Barcelona, Spain., Kutny M; Children's Hospital of Alabama, Birmingham, AB., Zarnegar-Lumley S; Vanderbilt University, Nashville, TN., Redell M; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX., Cooper S; Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD., Bertrand Y; CHU Lyon, Hospices Civils de Lyon, Lyon, France., Petit A; Hôpital Armand Trousseau, Paris, France., Krystal J; The Steven and Alexandra Cohen Children's Medical Center of New York, New York, NY., Metzler M; Universitätsklinikum Erlangen, Erlangen, Germany., Lancaster D; The Royal Marsden NHS Foundation Trust, London, United Kingdom., Bourquin JP; University Children's Hospital, Zürich, Switzerland., Motwani J; Birmingham Children's Hospital, Birmingham, United Kingdom., van der Sluis IM; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., Locatelli F; IRCCS Ospedale Pediatrico Bambino Gesù, Catholic University of the Sacred Heart, Rome, Italy., Roth ME; University of Texas MD Anderson Cancer Center, Houston, TX., Hijiya N; Columbia University Irving Medical Center, New York, NY., Zwaan CM; Department of Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

المصدر: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Mar 01; Vol. 42 (7), pp. 821-831. Date of Electronic Publication: 2023 Nov 30.

نوع المنشور: Clinical Trial, Phase I; Journal Article

بيانات الدورية: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myeloid, Chronic-Phase*/drug therapy , Quinolines*/adverse effects, Adolescent ; Adult ; Child ; Child, Preschool ; Humans ; Infant ; Aniline Compounds/adverse effects ; Nitriles/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Treatment Outcome

المؤلفون: Tokatlı M; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Türkiye, Ismayilov R; Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Türkiye, Erkin Çınar O; Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Türkiye, Haznedaroğlu İC; Hacettepe University Faculty of Medicine, Department of Hematology, Ankara, Türkiye

المصدر: Turkish journal of haematology : official journal of Turkish Society of Haematology [Turk J Haematol] 2024 Mar 01; Vol. 41 (1), pp. 59-60. Date of Electronic Publication: 2023 Dec 28.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Galenos Yayinevi Country of Publication: Turkey NLM ID: 9606065 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1308-5263 (Electronic) Linking ISSN: 13007777 NLM ISO Abbreviation: Turk J Haematol Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/complications , Leukemia, Myeloid*/complications , Antineoplastic Agents*/adverse effects , Leukemia, Myeloid, Chronic-Phase*/complications, Humans ; Constriction, Pathologic/complications ; Pyrimidines/adverse effects ; Protein Kinase Inhibitors/adverse effects

المؤلفون: Ielo C; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Scalzulli E; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Carmosino I; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Pepe S; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Bisegna ML; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Martelli M; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy., Breccia M; Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, Rome, Italy.

المصدر: Leukemia & lymphoma [Leuk Lymphoma] 2023 Dec; Vol. 64 (14), pp. 2324-2326. Date of Electronic Publication: 2023 Sep 10.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 9007422 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1029-2403 (Electronic) Linking ISSN: 10268022 NLM ISO Abbreviation: Leuk Lymphoma Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/adverse effects , Leukemia, Myeloid, Chronic-Phase*/diagnosis , Leukemia, Myeloid, Chronic-Phase*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy, Humans ; Imatinib Mesylate/adverse effects ; Protein Kinase Inhibitors/adverse effects ; Treatment Outcome

المؤلفون: Shah NP; 1UCSF Helen Diller Family Comprehensive Cancer Center., Bhatia R; 2O'Neal Comprehensive Cancer Center at UAB., Altman JK; 3Robert H. Lurie Comprehensive Cancer Center of Northwestern University., Amaya M; 4University of Colorado Cancer Center., Begna KH; 5Mayo Clinic Comprehensive Cancer Center., Berman E; 6Memorial Sloan Kettering Cancer Center., Chan O; 7Moffitt Cancer Center., Clements J; 8CML Buster Foundation., Collins RH; 9UT Southwestern Simmons Comprehensive Cancer Center., Curtin PT; 10City of Hope National Medical Center., DeAngelo DJ; 11Dana-Farber/Brigham and Women's Cancer Center., Drazer M; 12The UChicago Medicine Comprehensive Cancer Center., Maness L; 13Fred and Pamela Buffett Cancer Center., Metheny L; 14Case Comprehensive Cancer Center University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute., Mohan S; 15Vanderbilt-Ingram Cancer Center., Moore JO; 16Duke Cancer Institute., Oehler V; 17Fred Hutchinson Cancer Center., Pratz K; 18Abramson Cancer Center at the University of Pennsylvania., Pusic I; 19Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine., Rose MG; 20Yale Cancer Center/Smilow Cancer Hospital., Shomali W; 21Stanford Cancer Institute., Smith BD; 22The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins., Styler M; 23Fox Chase Cancer Center., Talpaz M; 24University of Michigan Rogel Cancer Center., Tanaka TN; 25UC San Diego Moores Cancer Center., Tantravahi S; 26Huntsman Cancer Institute at the University of Utah., Thompson J; 27Roswell Park Comprehensive Cancer Center., Tsai S; 28UCLA Jonsson Comprehensive Cancer Center., Vaughn J; 29The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute., Welborn J; 30UC Davis Comprehensive Cancer Center., Yang DT; 31University of Wisconsin Carbone Cancer Center., Sundar H; 32National Comprehensive Cancer Network., Gregory K; 32National Comprehensive Cancer Network.

المصدر: Journal of the National Comprehensive Cancer Network : JNCCN [J Natl Compr Canc Netw] 2024 Feb; Vol. 22 (1), pp. 43-69.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Harborside Press Country of Publication: United States NLM ID: 101162515 Publication Model: Print Cited Medium: Internet ISSN: 1540-1413 (Electronic) Linking ISSN: 15401405 NLM ISO Abbreviation: J Natl Compr Canc Netw Subsets: MEDLINE

مواضيع طبية MeSH: Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/diagnosis , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/genetics , Leukemia, Myeloid, Chronic-Phase*/drug therapy, Humans ; Blast Crisis/chemically induced ; Blast Crisis/drug therapy ; Blast Crisis/genetics ; Protein Kinase Inhibitors/adverse effects ; Philadelphia Chromosome ; Fusion Proteins, bcr-abl/genetics